12 February 2024
In a bid to extend the lives of our beloved dogs and enhance their well-being, the first-ever anti-aging tablet designed for canines is now in the trial phase. Boo, an 11-year-old whippet residing in Pennsylvania, is leading the charge as the initial participant in this clinical trial conducted by Loyal, a veterinary medicine startup. Loyal is already awaiting FDA approval for another groundbreaking anti-aging product intended for larger dogs over 7 years old and weighing more than 40 pounds.
The STAY study is a significant endeavor involving over 1,000 aging dogs from diverse breeds and sizes across 50 locations in the United States. Its primary objective is to assess the efficacy of Loyal’s new medication, known as LOY-002, in extending the lifespan of dogs. The ambitious aim is to add at least one more year to the lives of these aging canines.
Clarifying that participation in a clinical trial doesn’t confirm a drug’s effectiveness is essential. Rather, it serves as a rigorous evaluation to determine its efficacy. As Daniel Promislow, an aging expert not directly associated with Loyal’s drug development, notes, “A clinical trial doesn’t mean the drug works — it means we’re going to test whether it works.”
Boo’s New Routine
Boo’s daily life has taken an exciting turn with LOY-002. He now eagerly consumes flavored tablets with a beef-like taste, making his medication intake a delightful experience akin to receiving a treat.
While the exact composition of LOY-002 remains undisclosed, it primarily aims to enhance canine metabolism, which tends to decline as dogs age. This medication targets dogs aged 10 and older, weighing more than 14 pounds, offering a potential game-changer in the realm of canine aging.
Although clinical results are anticipated to take several years to materialize, Loyal has an ambitious timeline in mind. The company aims for conditional FDA approval by early 2025, possibly granting pet owners access to this groundbreaking treatment before final results are available.
Concerns about affordability have been addressed by Loyal. LOY-002 is designed to be “affordable,” with costs expected to be in the “mid double-digits” per month range. Importantly, it will be available for direct purchase, eliminating the need for insurance.
With 1,000 dogs participating in Loyal’s trial, the study is poised to provide comprehensive data capable of detecting even a modest extension in healthy lifespan. If deemed safe and effective, this pioneering effort could hold profound significance for both dogs and their devoted human companions.